Characterization of long‐term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70246 ↗At a glance
Journal article in International Journal of Cancer, 2026. Written by Jona Laukhuf and 10 co-authors. Institution: Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany. Major MEDLINE topics: Melanoma, Uveal Neoplasms, Liver Neoplasms, Cancer Survivors. 18 references. The full text is freely available (open access, CC BY 4.0). Funded by: Junior Clinician Scientists Program of the University of Tuebingen.
Abstract (original language)
Patients with metastatic uveal melanoma (UM) have a poor prognosis. While long‐term survival data in cutaneous melanoma (CM) are promising, such data are lacking in UM and long‐term survivors are rare. In cases of metastases, the liver is affected in 90% of cases and is the main determinant of life expectancy. Immune checkpoint inhibitors (ICI) are less effective in UM than in CM. Therefore, liver‐directed therapies are of high relevance. We evaluated a large cohort of UM patients ( n = 167) who had developed liver metastases between 2005 and 2021. We focused on patients who survived 3 years or more from the initial diagnosis of liver metastases and precisely characterized this cohort with regard to systemic therapies (ST) and liver‐specific procedures applied. The last follow‐up (FU) date was October 31, 2024. We identified 33 long‐term survivors, representing 20% of the total cohort. Most patients had additional extrahepatic metastases (23/33; 70%), while 10 patients had liver metastases only. First‐line treatment in the metastatic setting consisted of liver‐directed therapies in most of the cases (27/33; 82%). 90% of the patients had received at least one liver‐specific procedure at any time point during FU and 85% had received ICI at any time point. Response evaluation revealed a high percentage of patients with disease control (DC) after the first ST (17/27; 63%) or first liver‐specific therapy (27/29; 93%), respectively. Notably, all patients with chemosaturation as their first liver‐specific procedure achieved DC. Further data are needed on the combination of liver‐directed therapy and ST, such as ICI or Tebentafusp.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany.
- Department of Diagnostic and Interventional Radiology, University Hospital Tuebingen, Tuebingen, Germany.
- Center of Radiology, Minimally Invasive Therapies and Nuclear Medicine, SLK-Kliniken Heilbronn, Academic Hospital of Ruprecht-Karls-University, Heidelberg, Germany.
- Department of Nuclear Medicine and Clinical Molecular Imaging, Eberhard Karls University of Tuebingen, Tuebingen, Germany.
- Department of General, Visceral and Thorax Surgery, Oberschwabenklinik, Ravensburg, Germany.
ORCID profiles: Andrea Forschner
Funding
- Junior Clinician Scientists Program of the University of Tuebingen
Cite
APA
Laukhuf, J., Wiens, L., Grözinger, G., Dittmann, H., Thiel, K., Leiter, U., Amaral, T., Nanz, L., Flatz, L., Reitmajer, M., & Forschner, A. (2026). Characterization of long‐term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021. International Journal of Cancer. https://doi.org/10.1002/ijc.70246
Vancouver
Laukhuf J, Wiens L, Grözinger G, Dittmann H, Thiel K, Leiter U, et al. Characterization of long‐term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021. International Journal of Cancer. 2026. doi:10.1002/ijc.70246
BibTeX
@article{Laukhuf2026,
author = {Laukhuf, Jona and Wiens, Lisa and Grözinger, Gerd and Dittmann, Helmut and Thiel, Karolin and Leiter, Ulrike and Amaral, Teresa and Nanz, Lena and Flatz, Lukas and Reitmajer, Markus and Forschner, Andrea},
title = {Characterization of long‐term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70246}
}
EUVIMED